Germ cell tumours (GCTs) most often arise in the gonads, but some develop extragonadally.
The aim of this study was to examine gender- and race-specific trends in incidence and survival of gonadal (GGCTs) and extragonadal GCTs (EGCTs) in the US from 1973 to 2007. We also examined the topographical distribution of EGCTs by race and gender. We estimated age-specific and age-standardized incidence rates and 5-year relative survival rates (RSR) of GCTs using the Surveillance, Epidemiology and End Results (SEER) Program (SEER nine registries). GCTs and their topographical sites were identified using ICD-O morphology and topography codes. Of 21 170 GCTs among males, 5.7% were extragonadal (Whites 5.5%; Blacks 16.3%). Of 2093 GCTs among females, 39.3% were extragonadal (Whites, 36.9%; Blacks 51.0%). The incidence of GGCT was much higher among White (56.3/1 000 000) than Black males (10.0/1 000 000), while there was no difference in incidence between White and Black females (3.2/1 000 000). The rates of EGCT among men and women of both races were similar (range:1.9-3.4/1 000 000). The most frequent extragonadal sites were mediastinum among males and placenta among females. The 5-year RSR of testicular GCT was higher among Whites (97%) than Blacks (90%), as was the 5-year RSR of ovarian GCT (Whites, 92%; Blacks 85%). In general, the 5-year RSRs of EGCTs were lower than the 5-year RSRs of GGCTs. The different incidence trends of GGCTs and EGCTs and distinct age-specific incidence patterns by anatomical site of EGCTs suggest that GGCTs and EGCTs may have different aetiologies.
Written by:
Stang A, Trabert B, Wentzensen N, Cook MB, Rusner C, Oosterhuis JW, McGlynn KA. Are you the author?
Institut für Klinische Epidemiologie, Medizinische Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA; Josephine Nefkens Institute, Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.
Reference: Int J Androl. 2012 Aug;35(4):616-25.
doi: 10.1111/j.1365-2605.2011.01245.x
PubMed Abstract
PMID: 22320869
UroToday.com Testicular Cancer Section